Phase III clinical trial - Sein métastatique RH+
SERENA-6 D8534C00001
Sein métastatique RH+
Ouvert depuis le: 04.24.2024
Site: Paris
Ouvert depuis le: 01.12.2022
Site: Saint-Cloud
Public cible
Adulte
A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study
Description de l'essai
The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation
Liens utiles
FRANCOIS-CLEMENT BIDARD
Investigateur principal
ETIENNE BRAIN
Investigateur principal